SAN ANTONIO--(BUSINESS WIRE)--Results from three studies being presented at the 37th Annual San Antonio Breast Cancer Symposium this week underscore the unique abilities of bioTheranostics’ Breast Cancer IndexSM molecular test, providing additional strong evidence of both its predictive and prognostic power.
According to Nicolas Barthelemy, president and CEO of bioTheranostics, the findings add to the growing body of research establishing the Breast Cancer Index as the “biomarker of endocrine response.” “Only about 3-5 percent of breast cancer patients in the United States benefit from extended endocrine therapy—which is associated with significant side effects and safety challenges,” Barthelemy said. “The Breast Cancer Index is distinct in that it provides molecular information that facilitates selection of women who are likely to benefit from continuing endocrine treatment beyond five years, thus potentially sparing those unlikely to benefit from adverse events and toxicities that can negatively affect their health and quality of life.”
Help employers find you! Check out all the jobs and post your resume.
